Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.

From the monthly archives: September 2020

We are pleased to present below all posts archived in 'September 2020'. If you still can't find what you are looking for, try using the search box.

AMSBIO: Announce StemFit® for MSC - a new and optimized medium for expansion and maintenance of Mesenchymal Stem Cells (MSC)**.

AMSBIO announce StemFit® for MSC - a new and optimized medium for expansion and maintenance of Mesenchymal Stem Cells (MSC)**. StemFit® for MSC is the latest addition to the StemFit® family of stem cell media.  It is a chemically defined and human/animal origin free medium, optimized for the isolation and culture of MSCs from bone marrow (BM-MSC), umbilical cord (UC-MSC), and adipose (ADSC) under serum-free, human platelet lysate free conditions.


Read the rest of entry »

Enesi Pharma: ImplaVax®-Enabled, Solid-Dose Modified Live Virus Vaccine

Enesi Pharma’s ImplaVax®-Enabled, Solid-Dose Modified Live Virus Vaccine Produces Neutralising Antibody and T-Cell Responses Equivalent to Liquid Vaccine Delivered via Needle and Syringe

Read the rest of entry »

Enesi Pharma: Appoints Vaccine Development Expert Dr Keith Howard As Chief Scientific Officer

OXFORD, UK – 28 September 2020 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its world leading ImplaVax® technologies, is delighted to announce the appointment of Keith Howard as Chief Scientific Officer.

Read the rest of entry »

Yourgene Health: Announces the launch of Yourgene Genomic Services

Manchester, UK – 28 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the launch of Yourgene Genomic Services, an integration and expansion of the Company’s international service laboratory offerings.  Yourgene Genomic Services becomes a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations.  

Read the rest of entry »

RSSL launches bespoke nitrosamine test service

Reading Scientific Services Ltd (RSSL) has expanded its pharmaceutical assessment capabilities with the introduction of a robust analytical method designed to determine the presence of nitrosamines. Using highly-sensitive mass spectrometers in conjunction with a range of separation techniques, the new service can not only reach exceptionally low regulatory thresholds, but also accommodate a wide variety of pharmaceutical products and active species.

Read the rest of entry »

Discovery Park: Psyros Diagnostics & VisusNano join innovation community

The innovation community is continuing to evolve at Discovery Park, the Life Sciences Opportunity Zone for ambitious and growing life sciences companies, as new tenants move in and others continue to develop. New entrants Psyros Diagnostics and VisusNano have both taken laboratory and office space at the Park.

Read the rest of entry »

Evotec expands at Milton Park to become one of its largest occupiers

Evotec, a leading drug discovery alliance and development partnership company, has taken additional office and laboratory space at Milton Park, one of the leading science and technology communities in Europe, to bring its total occupation to 192,745 sq ft making it one of the largest occupiers on the Park.

Read the rest of entry »

Yourgene Health: US distribution agreement for DPYD and other products

Manchester, UK - Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has appointed Immuno-Biological Laboratories Inc (‘IBL-America’), a supplier of in-vitro diagnostic kits for the medical device and research industry, as a non-exclusive distributor for several PCR (‘polymerase chain reaction’) tests across Yourgene’s reproductive health and oncology portfolios in the US.   

Read the rest of entry »

ARECOR to Present at EASD 2020 - Oral Presentation of Phase I Clinical Trial of AT247, A Novel Ultra Rapid Acting Insulin

Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I study investigating the PD, PK and safety of AT247 in comparison to insulin aspart, NovoRapid®, and fast insulin aspart, Fiasp®, has been selected for oral presentation at the upcoming European Association for the Study of Diabetes (EASD) virtual meeting which will be held from 21-25 September 2020.  Abstract #55 is available online.

Read the rest of entry »

OBN: CEO Update from John Harris

As the country returns to some semblance of normality, despite the recent guidelines, I’d like to take the opportunity to bring our Members, Sponsors and Supporters up to date with the world of OBN. 

OBN responded quickly and decisively to the unprecedented challenge that COVID 19, the lockdown and subsequent restrictions brought and I am delighted and proud of the OBN team’s response to such extraordinary circumstances, not least of which entailed the successful transformation of BioTrinity® from a physical event to become the UK’s first fully digital conference in the tightest of timescales.

Read the rest of entry »

Pages: Previous123NextReturn Top

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.